SciSparc's NeuroThera Launches Phase IIb Trial for Tourette Syndrome Drug
SPRC sits 56% above its 52-week low of $2.98 on light trading volume (0.1× avg).
Summary
NeuroThera Labs, SciSparc's majority-owned subsidiary, has initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, its cannabinoid-based treatment for Tourette Syndrome. The trial follows positive Phase IIa results showing a 21% average tic reduction and will also include sites at Yale and Tel Aviv Sourasky Medical Center. This marks a concrete advancement in the clinical program, moving from regulatory clearance to active patient enrollment. The company faces a tight financial position, with a recent 20-F noting substantial doubt about its ability to continue as a going concern, making trial progress critical. The Phase IIb study is a randomized, double-blind, placebo-controlled crossover trial with primary efficacy readout at weeks 12 and 26.
At the time of this announcement, SPRC was trading at $4.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $2.98 to $80.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.